Taysha Gene Therapies announced the United States Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. RMAT designation was granted following the FDA’s review of clinical data supporting the potential of TSHA-102 to address the unmet medical need for patients with Rett syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
- Apple upgraded, Tesla downgraded: Wall Street’s top analyst calls
- Neurogene initiated with an Outperform at Leerink
- Taysha Gene Therapies initiated with an Overweight at Piper Sandler